Trial Profile
A Phase IV Multicentre, Randomized Double-blind, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Raptiva in the Treatment of Subjects With Moderate to Severe Chronic Plaque Psoriasis Involving Palms and/or Soles, With or Without Pustules.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Efalizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 24 Oct 2009 New trial record